Microcap Ledger Curis Inc $CRIS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Lexington, MA
- Fiscal year end
- December 31
- Shares outstanding
- 2,090,077 [10-Q 2026-08-14]
What the company doesAI summary of filing
Curis Inc. is a biotechnology company developing emavusertib (CA-4948), an oral small molecule inhibitor of IRAK4 and FLT3 proteins, currently in clinical-stage development for hematologic malignancies including relapsed/refractory primary central nervous system lymphoma and chronic lymphocytic leukemia. The company is pre-revenue and has incurred substantial losses since inception, with operations funded through equity financings and royalty-related proceeds. Curis generates potential future revenue through royalty payments on sales of compounds developed under its license agreements, particularly with Aurigene Discovery Technologies for emavusertib and related programs, and historically received royalties on Erivedge sales from Genentech until divesting that asset in November 2025. The company requires substantial additional capital to fund development of emavusertib through regulatory approval and commercialization. [10-K 2026-03-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$32.78M | −$18.65M | $5.07M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $9.44M | −$7.58M | −$27.20M | $5.06M | [10-K 2026-03-24] |
| FY ended Dec 2024 | $10.91M | −$43.39M | −$39.56M | $20.00M | [10-K 2026-03-24] |
- Quarterly cash burn
- −$9.32M
- Cash runway Estimate
- ~1.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 8,466,957 | [10-Q 2024-11-14] |
| 2025-03-27 | 8,487,818 | [10-K 2025-03-31] |
| 2025-05-02 | 10,462,250 | [10-Q 2025-05-06] |
| 2025-08-01 | 12,498,853 | [10-Q 2025-08-05] |
| 2025-11-04 | 12,928,853 | [10-Q 2025-11-06] |
| 2026-03-20 | 39,978,693 | [10-K 2026-03-24] |
| 2026-05-08 | 38,978,693 | [10-Q 2026-05-13] |
| 2026-08-11 | 2,090,077 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-08-10; declared effective 2026-08-12 [S-1 2026-08-10]
Listing status
Current status: 6 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-30] |
| 2026-05-01 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-01] |
| 2026-02-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-09] |
| 2025-10-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-24] |
| 2025-08-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-22] |
| 2025-02-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-27] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-13 | 424B4 | Prospectus or prospectus supplement |
| 2026-08-10 | S-1 | Registration statement |
| 2026-07-30 | 8-K | Listing notice or transfer |
| 2026-07-02 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-07-01 | 8-K | Charter, bylaws or fiscal year change |
| 2026-07-01 | 8-K | Charter, bylaws or fiscal year change |
| 2026-06-25 | 8-K | Shareholder vote results |
| 2026-06-05 | DEF 14A | Proxy statement |
| 2026-05-22 | PRE 14A | Proxy statement |
| 2026-05-22 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $CRIS
Email me when Curis Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.